SOM Biotech Announces Poster Presentation on the Repurposing of Eravacycline for the Treatment of SARS-CoV-2
SOM Biotech, a biopharmaceutical company specialising in the repositioning of existing drugs for the treatment...
Programme SOM0208 for the Treatment of Niemann–Pick Type C Disease
SOM0208 is a small molecule for the treatment of Niemann–Pick C disease.
Niemann–Pick type C is a lysosomal storage disorder caused by defects in the intracellular transport and metabolism of cholesterol and glycolipids. The disease has a broad clinical spectrum. Affected individuals may have enlargement of the spleen (splenomegaly) and liver (hepatomegaly), or enlarged spleen or liver combined (hepatosplenomegaly), but this finding may be absent in later onset cases. Prolonged jaundice or elevated bilirubin can present at birth.
More About This Company
SOM Biotech Announces in Vitro Confirmation of Drug Candidates for Covid-19 in Collaboration with Ewha Woman’s University
SOM Biotech, a clinical-stage drug discovery and development company, announces the in vitro validation of...
Partnership presentation
Unique advantages of SOMAI PRO include identification of new mechanisms of action of drugs (biological...
SOM Biotech: A Top Spanish Start-Up to Follow in 2020
SOM Biotech has made Sifted's list as one of the Top Spanish Start-ups to follow...